Precision Medicine in Oncology® Articles

Expert Shares Advantages, Challenges With Liquid Biopsies in Cancer Care
Geoffrey Oxnard, MD, discusses testing error underlying liquid biopsy discordance, steps clinicians can take to optimize liquid biopsy, and where he sees this evolving in the treatment landscape for patients with cancer.
TLR Agonists Emerge as Potential New Partner for Checkpoint Inhibitors
Toll-like receptors, a group of proteins that are components of innate immunity, are emerging as promising targets in a new wave of immunotherapies under development.
Sayeh Lavasani, MD, MS, discusses the application of gene assays in the management of patients with hormone receptor-positive breast cancer, as well as ongoing research in this space.
Role of Liquid Biopsies Still Needs Refining in Breast Cancer
Aditya Bardia, MD, MPH, discusses the potential role of circulating tumor cells and circulating tumor DNA testing in patients with breast cancer.
Liquid Biopsy Screening Protocol Aims to Identify Actionable Targets in mCRC
Kristen Ciombor, MD, MSCI, discusses the promise of liquid biopsies in the rapidly evolving metastatic colorectal cancer paradigm and the potential implications of the COLOMATE trial.
FDA Expands Approval of PD-L1 IHC 22C3 pharmDX Assay in NSCLC
The FDA has expanded the approval of the PD-L1 IHC 22C3 pharmDX assay, allowing the test to be used as a companion diagnostic to identify more patients with stage III or metastatic non–small cell lung cancer who can undergo first-line treatment with pembrolizumab (Keytruda).
Personalized Medicine Progressing in Premenopausal Breast Cancer
Joyce A. O’Shaughnessy, MD, discusses the clinical implications of the TEXT and SOFT trials for women with premenopausal HR-positive, HER2-negative breast cancer, as well as unanswered questions that remain with adjuvant endocrine therapy.
Liquid Biopsies Reliably and Quickly Detect Genomic Biomarkers in Metastatic NSCLC
Vassiliki A. Papadimitrakopoulou, MD, highlights the implications of the NILE study on clinical practice and sheds light on the potential future utility of liquid biopsies in non–small cell lung cancer.
Genomic Assays Advance Personalized Care in Early-Stage Breast Cancer
Mariana Chavez Mac Gregor, MD, MSc, discusses the optimal applications of these assays in patients with early-stage, HR-positive/HER2-negative breast cancer and shed light on the overall outlook of personalized medicine in this setting.
Study Validates Speed, Accuracy of Liquid Biopsies Identifying NSCLC Biomarkers
A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non–small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.
Publication Bottom Border
Border Publication